Vericel Co. (NASDAQ:VCEL – Free Report) – Analysts at HC Wainwright increased their FY2023 EPS estimates for Vericel in a note issued to investors on Thursday, September 21st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of ($0.25) for the year, up from their prior estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $44.50 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Vericel’s Q1 2024 earnings at ($0.21) EPS, Q2 2024 earnings at ($0.01) EPS, Q3 2024 earnings at $0.02 EPS, Q4 2024 earnings at $0.43 EPS, FY2024 earnings at $0.26 EPS and FY2025 earnings at $0.82 EPS.
A number of other equities analysts also recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $44.00 price objective on shares of Vericel in a report on Thursday. Truist Financial reaffirmed a “hold” rating and issued a $39.00 price objective on shares of Vericel in a report on Thursday. StockNews.com started coverage on shares of Vericel in a report on Thursday, August 17th. They issued a “hold” rating for the company. Finally, BTIG Research raised shares of Vericel from a “neutral” rating to a “buy” rating and set a $39.00 price objective for the company in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.63.
Vericel Trading Down 0.6 %
VCEL stock opened at $34.00 on Monday. Vericel has a twelve month low of $17.30 and a twelve month high of $39.90. The company has a market capitalization of $1.62 billion, a P/E ratio of -117.24 and a beta of 1.76. The firm has a 50 day simple moving average of $34.24 and a 200-day simple moving average of $33.24.
Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Vericel had a negative net margin of 7.39% and a negative return on equity of 6.90%. The business had revenue of $45.92 million during the quarter, compared to the consensus estimate of $42.14 million. During the same quarter last year, the company earned ($0.19) earnings per share. The business’s quarterly revenue was up 24.7% compared to the same quarter last year.
Institutional Investors Weigh In On Vericel
Hedge funds have recently added to or reduced their stakes in the stock. Pinebridge Investments L.P. lifted its stake in Vericel by 718.0% in the second quarter. Pinebridge Investments L.P. now owns 818 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 718 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Vericel during the second quarter valued at about $39,000. Ameritas Advisory Services LLC bought a new stake in shares of Vericel during the first quarter valued at about $41,000. Fifth Third Bancorp raised its stake in shares of Vericel by 38.3% during the second quarter. Fifth Third Bancorp now owns 1,210 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 335 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Vericel by 174.3% during the first quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,060 shares in the last quarter.
Insider Buying and Selling at Vericel
In other Vericel news, Director Robert L. Md Zerbe sold 1,000 shares of the firm’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $38.84, for a total value of $38,840.00. Following the sale, the director now directly owns 33,395 shares in the company, valued at $1,297,061.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.20% of the stock is currently owned by company insiders.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Featured Stories
- Five stocks we like better than Vericel
- How to Buy Metaverse Stock Step by Step
- 3 Reasons This Sleeping Giant Is About To Wake Up
- Are Stock Buybacks Good for the Average Investor?
- MarketBeat Week in Review – 9/18 – 9/22
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
